Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
East Bay Institute for Research and Education |
---|---|
Information provided by: | East Bay Institute for Research and Education |
ClinicalTrials.gov Identifier: | NCT00539175 |
1. Objectives:
2. Research Design
This is a double blinded, randomized, placebo-controlled study of 120 patients with painful diabetic neuropathy. These 120 will be randomly assigned treatments utilizing Photon Therapy, using a defined treatment protocol. We expect that some patients will drop out, and our goal is 100 treated patients, for statistical purposes. The Photon Therapy group will be split into two groups, one group that receives Active Photon Therapy and one group that will be treated with the same type of equipment that has been modified to emit no infrared photons (Non Active Photon Therapy Group ("Placebo")). The patients in the "Non Active Photon Therapy Group" will be offered an Active Photon Treatment Session after completion of the study. The patients in the Photon Therapy Groups will be randomized. There will also be an Historical Control Group of patients, fifty, will have received traditional medical interventions (e.g., narcotics, seizure medications) in traditional medical practices. Data from these individuals will be used to calculate potential cost savings.
3. Methodology:
Subjects who meet the inclusion and exclusion criteria and have signed a valid informed consent will be eligible to participate in the study. After screening, subjects in the Photon Therapy groups (both active and nonactive) will undergo four treatment sessions. The first treatment session will vary from the second, third and fourth. During all treatment session, each patient will be imaged with the TIP Infrared Camera before, and after treatment. Infrared imaging can visualize skin temperature changes in a noninvasive manner (2). The first treatment will utilize slightly different protocol than subsequent visits, reduced Photon dosage, 120 instead of 240 joules. Proprioception and protective sensation, characterized by the Semmes-Weinstein monofilament test, and visual and analog pain scoring will also be evaluated before and after each Photon Therapy treatment.
4. Finding:
To date, we have just completed 120 patients, using a block randomization scheme not previously reported in this field. We have collected data on nerve function, pain, quality of life, and skin circulation. The data will remain stored until the study is complete to preserve the blinded nature of the project. Data analysis is still incomplete.
4. Clinical Significance
Diabetic neuropathy is a chronic and progressive condition that potentially leads to disabling pain, and worse, amputation, for many individuals in the United States each year. Present treatments utilize antiseizure medications, opiate analgesics, and antidepressants, and are inconsistently effective. Development of a new treatment strategy potentially could have significant benefit for a great many patients.
Condition | Intervention |
---|---|
Diabetic Neuropathy, Painful Diabetic Neuralgia Diabetic Polyneuropathy Diabetic Mononeuropathy |
Device: infrared light Device: infrared light; placebo |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Treatment of Painful Diabetic Neuropathy With Photon Stimulation |
Enrollment: | 120 |
Study Start Date: | October 2004 |
Study Completion Date: | October 2006 |
Arms | Assigned Interventions |
---|---|
2: Active Comparator
active treatment with infrared light
|
Device: infrared light
pulsed infrared light will be applied to feet, ankles and popliteal fossae of patients with diabetic neuropathy
|
1: Placebo Comparator
sham (placebo) treatment without infrared light
|
Device: infrared light; placebo
patients will be exposed to the same machine used to provide pulsed infrared light, but the light emitting diodes will not be activated. All other aspects of the treatment will be the same. The patient and investigator will be blind to treatment assignment.
|
Ages Eligible for Study: | 18 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
VA Northern California Health Care System | |
Martinez, California, United States, 94553 |
Principal Investigator: | Arthur LM Swislocki, MD | VA Northern California Health Care System; UC Davis School of Medicine |
Study ID Numbers: | Swislocki-1 |
Study First Received: | October 2, 2007 |
Last Updated: | October 3, 2007 |
ClinicalTrials.gov Identifier: | NCT00539175 |
Health Authority: | United States: Food and Drug Administration |
diabetes mellitus neuropathy diabetic neuropathy |
Diabetic Neuropathies Neuralgia Polyneuropathies Diabetes Mellitus Endocrine System Diseases Pain Mononeuropathies |
Signs and Symptoms Neuromuscular Diseases Peripheral Nervous System Diseases Neurologic Manifestations Endocrinopathy Diabetes Complications |
Nervous System Diseases |